ZYME
Zymeworks Inc.
Company Overview
| Mkt Cap | $1.27B | Price | $24.04 |
| Volume | 464.84K | Change | -4.22% |
| P/E Ratio | -15.6 | Open | $25.04 |
| Revenue | $106.0M | Prev Close | $25.10 |
| Net Income | $-81.1M | 52W Range | $11.02 - $29.75 |
| Div Yield | N/A | Target | $40.15 |
| Overall | 51 | Value | 60 |
| Quality | 55 | Technical | 40 |
No chart data available
About Zymeworks Inc.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. The Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Latest News
Zymeworks (ZYME) Gets a Buy from Wells Fargo
Zymeworks Authorizes 2026 Share Repurchase Program, Affirms Liquidity
Citi Reaffirms Their Buy Rating on Zymeworks (ZYME)
Zymeworks’ Earnings Call Balances Progress And Pressure
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ZYME | $24.04 | -4.2% | 464.84K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |